Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾ÏÀÇ ³ú½ÇÁú ¹× ³ú¸·ÀüÀÌ Brain Metastasis and Leptomeningeal Carcinomatosis in Breast Cancer

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 3È£ p.464 ~ 474
¼Ò¼Ó »ó¼¼Á¤º¸
ÀåÀ±¼ö/Yoon Soo Chang

Abstract

¼­·Ð
°íÇüÁ¾¾çÀÇ ³ú½ÇÁúÀüÀÌ´Â 20%¡­40%ÀÇ ¾ÏȯÀÚ¿¡¼­ ¹ß»ýÇϸç, 5%¡­8%¿¡¼­´Â ¿¬¼ö¸· ¾ÏÁ¾
ÁõÀ¸·Î ³ªÅ¸³­´Ù. ³ú½ÇÁú ȤÀº ¿¬¼ö¸· ¾ÏÁ¾ÁõÀ» À¯¹ßÇÏ´Â ´ëÇ¥ÀûÀÎ ¾ÏÁ¾À¸·Î´Â Æó¾Ï, À¯¹æ
¾Ï, ¾Ç¼ºÈæ»öÁ¾, ¸²ÇÁÁ¾ ¹× ¹éÇ÷º´ÀÌ ÀÖ´Ù. ³ú½ÇÁú ÀüÀÌ´Â ¹æ»ç¼±ÇÐÀû °Ë»ç¿¡ ÀÇÇØ º¸´Ù ½±
°Ô Áø´ÜÀÌ °¡´ÉÇÑ ¹Ý¸é, ¿¬¼ö¸· ¾ÏÁ¾ÁõÀÇ °¡Àå º¸ÆíÀûÀÎ Áø´Ü¹æ¹ýÀÎ ³úô¼ö¾×ÀÇ ¼¼Æ÷ÇÐÀûÀÎ
°Ë»ç´Â ³ú½ÇÁúÀÇ ÀüÀ̺´º¯À¸·ÎºÎÅÍ À¯¸®µÈ ¼¼Æ÷¿¡ ÀÇÇؼ­µµ ¾ç¼ºÀÇ °á°ú°¡ ¾ò¾îÁú ¼ö ÀÖ´Ù.
¹Ý¸é¿¡ ¿¬¼ö¸· ¾ÏÁ¾ÁõÀÌ ÀǽɵǴ °æ¿ì¿¡µµ ¼¼Æ÷ÇÐÀû °Ë»ç»ó À½¼ºÀÇ °á°ú°¡ ³ªÅ¸³ª´Â °æ¿ì
µµ ÀûÁö ¾Ê´Ù. À¯¹æ¾Ï¿¡¼­ÀÇ ³úÀüÀÌ ¶Ç´Â ¿¬¼ö¸· ¾ÏÁ¾Áõ¿¡ ´ëÇÑ ¿¬±¸´Â ±×¸® ¸¹Áö ¾Ê°í °¢
±â ´Ù¸¥ Ä¡·á ¹æ¹üµéÀÇ Æò°¡¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ÀüÇâÀû ¹«ÀÛÀ§ ¿¬±¸ °á°ú°¡ °ÅÀÇ ¾ø´Ù.
À¯¹æ¾ÏÀÇ ³ú½ÇÁúÀüÀÌ º´¼Ò¿¡ ´ëÇÑ Ä¡·á´Â Àü³ú ¹æ»ç¼± Ä¡·á°¡ Ç¥ÁØ Ä¡·á¹æ¹ýÀ¸·Î µÇ¾î ÀÖ
À¸¸ç Àü½Å Ç׾Ͼ๰¿ä¹ý, ¼ö¸·°­³» Ç׾Ͼ๰¿ä¹ý µîµµ º´¿ëµÇ°í ÀÖ´Ù. ÀÌ¿Í °°Àº Ä¡·á¹æ¹ýµé
Àº ¿¬¼ö¸· ¾ÏÁ¾ÁõÀÇ Ä¡·á¿¡µµ ÀÌ¿ëµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ±× Ä¡·á°á°ú¿¡ ´ëÇÑ Æò°¡´Â Á¦´ë·Î µÇ
¾î ÀÖÁö ¾ÊÀº »óÅÂÀÌ´Ù. ÀúÀÚµéÀº ¿¬¼¼¾Ï¼¾ÅÍ ¹× ¿¬¼¼ÀÇ·á¿ø¿¡¼­ À¯¹æ¾ÏÀÇ ³ú½ÇÁúÀüÀÌ È¤Àº
¿¬¼ö¸· ¾ÏÁ¾ÁõÀ¸·Î Áø´ÜµÇ¾î Ä¡·á°¡ ½ÃÇàµÇ¾ú´ø ȯÀÚµéÀ» ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ¿©, À̵éÀÇ ÀÓ
»ó¾ç»ó°ú »ýÁ¸À²À» Á¶»çÇÏ¿´´Ù.

Purpose : Brain metastasis is estimated to occur in 20 to 40% of cancer patients, and
meningeal involvement has been reported in 5% to 8% of cancer patients. Even if the
prognosis is grave, standard treatment modality of brain metastasis or leptomeningeal
carcinomatosis has not been established. We evaluated the prognosis and the clinical
features of the brain and leptomeningeal metastasis of the breast cancer.
Materials and Methods : The 43 patients who was diagnosed as brain parenchymal
metastasis or leptomeningeal carcinomatosis clinically, radiologically and/or cytologically
were included in this study. The median age was 44(range: 27¡­61) years.
Results : The median duration from brain metastasis to death was 181 days(range:
8¡­1599), and the median duration from leptomeningeal carcinomatosis to death was 39
days(range: 25¡­152). Age(p=0.7174) and number of brain metastatic lesion(p=0.4097) did
not influence the survival, but the presence of other systemic metastatic lesion affected
the survival(p=0.0224). When we compared the survival rates of patients according to
treatment modality, the patients with systemic chemotherapy versus patients without
systemic chemotherapy showed differences(p=0.0009). Patients treated with whole brain
radiation only versus patients with whole brain radiation and other systemic
management also showed different survival rate(p=0.0009). But intrathecal chemotherapy
had no effect on survival. Well differentiated, solitary lesions were treated by operation
and/or ¥ã-knife surgery, and their effects were good.
Conclusion : Prolongation of survival was suggested with whole brain radiotherapy
combined with systemic treatment in brain or leptomeningeal metastasis. Further study
is expected to confirm this finding.

Å°¿öµå

Brain metastasis; Leptomeningeal carcinomatosis; Breast cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS